

Cutting-edge Research to be Presented at the PMC's 6th Annual Symposium on Malignant Pleural Mesothelioma


On September 24th global experts on malignant pleural mesothelioma will convene for the 6th Annual International Symposium on Malignant Pleural Mesothelioma.

LOS ANGELES, CALIFORNIA, U.S., August 30, 2016 /EINPresswire.com/ -- On September 24th global experts on malignant pleural mesothelioma will convene at the new Meyer & Renee Luskin Conference Center at UCLA for the 6th Annual International Symposium on Malignant Pleural Mesothelioma (MPM), a rare form of cancer that results from exposure to asbestos and commonly affects the lining of the chest—the pleura. The event is jointly hosted by UCLA and [the Pacific Mesothelioma Center](#) (PMC).

The Symposium is geared towards physicians and offers continuing medical education (CME) credit. It will also provide up-to-date information on mesothelioma for medical students, nurses and other healthcare professionals, as well as mesothelioma patients, their families and other interested parties. Topics will cover: options for intraoperative adjuvant therapies, updates from recent mesothelioma clinical trials, cryoablation in management of recurrent mesothelioma, the role of immunotherapy in advanced pleural mesothelioma, genetic immunotherapy

for malignant pleural mesothelioma and more.

The Symposium will be led by [Robert B. Cameron](#), MD, FACS, Director of the UCLA Mesothelioma Comprehensive Research Program and Chief of Thoracic Surgery at the West Los Angeles VA Medical Center. The roster of distinguished international faculty at the Symposium will include Edgar



PACIFIC
MESOthelioma
CENTER
at Pacific Heart, Lung & Blood Institute



UCLA

MEYER & RENEE
LUSKIN
CONFERENCE CENTER

G. Engleman, MD of Stanford University, Thierry M. Jahan, MD of UCSF, Edmund K. Moon, MD of the University of Pennsylvania, Richard Morgan, PhD of the University of Bradford, Daniel H. Sterman, MD of NYU, and Haining Yang, MD, PhD, of the University of Hawaii as well as local experts from UCLA.

"This event highlights medical advances in the treatment of mesothelioma and promising areas of new research," said Dr. Cameron. "One of the most exciting areas of research is immunotherapy, and our panel of experts will discuss genetic immunotherapy, dendritic cells, adoptive therapy with chimeric antigen receptor T cells, as well as a novel gene-modified stem cell immunotherapy. We even will have a discussion about the real possibility of the early detection and prevention of mesothelioma."

The Symposium is supported by: [Worthington & Caron](#), P.C., Eli Lilly & Company and the International Association of Heat & Frost Insulators.

Early Bird tickets can be purchased before September 9th online at <http://www.cme.ucla.edu/courses/>.

About The Pacific Mesothelioma Center:

The Pacific Heart, Lung & Blood Institute (PHLBI) is a 501(c)(3) non-profit medical research institute established in 2002. One of the divisions, The Pacific Mesothelioma Center (PMC) is focused on the treatment and prevention of malignant pleural mesothelioma (MPM). The exploration of innovative ideas forms the foundation of PMC's unique research program and provides the promise of future treatment breakthroughs. PMC is dedicated to educating the public on asbestos-related diseases and informing them of their best treatment options. PMC also connects newly diagnosed patients with patients that have been through treatment and provides assistance and emotional support.

Clare Cameron

The Pacific Mesothelioma Center

310-478-4678

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.